Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

GDC-1261

Drug and asset intelligence for GDC-1261 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Recent signals(1)

ClinicalJuly 13, 2026

Genentech's GDC-1261 Study Targets Advanced Prostate Cancer Safety and Activity

Genentech is conducting a study to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-1261 in advanced or metastatic prostate cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Roche — GDC-1261

July 13, 2026 · N/A

Indications

Prostate Cancer →

Therapeutic areas

Oncology · Prostate Cancer →

Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.